Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.36 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171432 | 0.98 | HRH3 (0.47) | HRH3L3MBTL3L3MBTL1BCAT2PDK2 | |
| SCHEMBL1171443 | 0.85 | HRH3 (0.53) | HRH3L3MBTL3L3MBTL1ACKR3PDK2 | |
| SCHEMBL1171295 | 0.85 | HRH3 (0.45) | HRH3ACKR3PDK2 | |
| SCHEMBL1171224 | 0.83 | HRH3 (0.55) | HRH3L3MBTL3L3MBTL1ACKR3PDK2 | |
| SCHEMBL1171413 | 0.83 | HRH3 (0.45) | HRH3PDK2 | |
| SCHEMBL13356084 | 0.79 | HRH3 (0.36) | HRH3L3MBTL3L3MBTL1PDK2 | |
| SCHEMBL1171271 | 0.79 | L3MBTL3 (0.46) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL1171155 | 0.79 | HRH3 (0.36) | HRH3L3MBTL3L3MBTL1PDK2 | |
| SCHEMBL1171258 | 0.79 | HRH3 (0.51) | HRH3 | |
| SCHEMBL1171259 | 0.79 | HRH3 (0.45) | HRH3L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | claimed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| WO-2007025596-A1 | PYRAZOLO [3 , 4-D] AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL3 3866/4885L3MBTL1 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.